https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-67Continuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-67https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-67#u45070Wed, 19 Aug 2026 05:15:06 +0000EyePoint shares dropped between 69% and 71% after a Phase 3 trial failed for Duravyu, a drug-device combination designed to treat age-related macular degeneration. The stock is tracking toward 16-month and 52-week lows following the setback. While the trial results were disappointing, the company maintains that the treatment still shows promise. The failure occurs as the company competes in a broader race to develop next-generation treatments for wet AMD.Why it mattersAge-related macular degeneration is a leading cause of vision loss. Duravyu represents a specialized approach combining a drug